How lived experience, decentralized trials, nonprofit drug development, and AI could reshape the path from scientific discovery to the patient.
Clinical research is built to answer extraordinarily complex scientific questions. But for the person deciding whether to participate in a trial, the questions are often much more immediate: How far will I have to travel? Can I take time away from work? Who will care for my children? Will I understand what is happening? And will anyone listen to what I need?
In our latest episode of The Humble Hang, we sat down with Craig Lipset, a longtime clinical research innovator whose career has spanned academic research centers, biotech, pharmaceutical leadership, patient advocacy, and nonprofit drug development. Formerly the head of clinical innovation at Pfizer, Craig helped pioneer the first fully decentralized clinical trial under an Investigational New Drug application and led an early initiative to return data to research participants. Today, he is co-founder and co-chair of the Digital Trials & Research Alliance (DTRA) and works across a number of initiatives seeking to make drug development more accessible, efficient, and responsive to patients.
Yet Craig’s perspective is not shaped by professional experience alone. His own patient journey managing a complex diagnosis, navigating health data, and seeking greater flexibility and agency in his own care has deeply informed the innovation he has pursued throughout his career.